The present invention provides novel compounds of the general Formula (I) as ligands to the melanocortin receptors and/or for treatment of disorders in the melanocortin system: ##STR00001## wherein X is (CH.sub.2).sub.n where n is 0, 1 or 2; R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 may be the same or different and are selected from hydrogen, halogen, alkyl having 1 to 5 carbon atoms, alkoxy having 1 to 5 carbon atoms, hydroxy, alkylsulphonyloxy, cyano, nitro, trihaloalkyl, sulpho or one of the structures given in Scheme 1; or two of R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 may together form a methylenedioxy or ethylenedioxy moiety; ##STR00002## R.sub.6, R.sub.7, R.sub.8 and R.sub.9 are the same or different and are selected from hydrogen, halogen, alkyl having 1 to 5 carbon atoms, alkoxy having 1 to 5 carbon atoms, hydroxy, amines (primary, secondary or tertiary) having 0, 1 or 2 carbon atoms, cyano, nitro, trihaloalkyl, amide or sulpho, and z where shown represents the point of attachment of the residue to the phenyl or pyrrole ring; and the pharmacologically active salts thereof.